GlaxoSmithKline (13015) is featuring their cardiovascular drugs Coreg CR and Arixtra.

Coreg CR (carvedilol phosphate) is a beta-blocker taken a once-a-day to treat hypertension, heart failure, and/or patients who have suffered cardiac damage due myocardial infarction.

Arixtra is the first in a new class of anticoagulants that offers once-daily dosing for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium and acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.